House dust mite allergy immunotherapy - Bial

Drug Profile

House dust mite allergy immunotherapy - Bial

Alternative Names: Allergovac DPT; Allergovac house dust mite; Allergovac house dust mite depot; BIA 15-2957

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bial
  • Developer BIAL
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis

Most Recent Events

  • 01 Sep 2017 Roxall Medicina Espana completes a phase I trial for Allergic rhinoconjunctivitis in Spain (SC) (NCT02881879)
  • 14 Nov 2016 BIAL Industrial Farmaceutca initiates a phase II trial for Allergic rhinoconjunctivitis in Spain (EudraCT2016-002944-18)
  • 01 Jul 2016 BIAL Industrial Farmacéutica initiates a phase I trial for Allergic rhinoconjunctivitis in Spain (SC) (NCT02881879)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top